Capd Continuous Ambulatory Peritoneal Dialysis — Cost, Top Hospitals & Success Rates | MyMedicPlus

Continuous Ambulatory Peritoneal Dialysis (CAPD) is a form of renal replacement therapy that uses the peritoneum — the natural membrane lining the abdominal cavity — as a semi-permeable dialysis membrane. In CAPD, a sterile dialysis solution (dialysate) is instilled into the peritoneal cavity via a permanent silicone catheter (typically a Tenckhoff catheter surgically placed in the lower abdomen), where it dwells for several hours. During this dwell time, waste products (urea, creatinine, potassium, phosphate) and excess fluid diffuse from the peritoneal capillaries into the dialysate by osmosis and diffusion. The used dialysate is then drained and replaced with fresh solution — a process called an exchange, performed manually by the patient 3–5 times per day.

CAPD is performed at home or in any clean environment without the need for machines or electricity, making it the most portable and independent form of dialysis. Each exchange takes approximately 30 minutes, and during the dwell time the patient is completely free to carry out normal daily activities — hence the term 'continuous ambulatory'. This approach provides continuous, gentle, steady-state dialysis 24 hours a day, seven days a week, more closely replicating the continuous function of the native kidney compared to intermittent haemodialysis.

CAPD was first described by Popovich, Moncrief, and colleagues in the late 1970s and has since become an established renal replacement modality used by approximately 200,000–300,000 patients worldwide. It requires comprehensive training — typically 1–2 weeks of structured education and practical instruction at a renal unit — before the patient begins independent home dialysis. Automated peritoneal dialysis (APD), a related modality using a cycler machine to perform exchanges overnight while the patient sleeps, is an increasingly popular alternative that offers a dialysis-free daytime for patients with employment and social commitments.

CAPD is indicated for patients with end-stage renal disease (ESRD), defined as a glomerular filtration rate (GFR) below 10–15 mL/min/1.73m², typically when accompanied by symptoms of uraemia (fatigue, nausea, fluid overload, cognitive impairment), hyperkalaemia unresponsive to conservative management, refractory fluid overload, or metabolic acidosis. The primary renal conditions leading to ESRD that are managed with CAPD include diabetic nephropathy (the leading cause of ESRD in most developed countries, accounting for approximately 40% of new dialysis starts), chronic glomerulonephritis, hypertensive nephrosclerosis, polycystic kidney disease, and reflux nephropathy.

CAPD is particularly well-suited to certain patient populations: those with cardiovascular instability (who may not tolerate the rapid fluid shifts of haemodialysis), patients with difficult vascular access, patients in remote areas far from haemodialysis centres, patients with active lifestyles wishing to maintain independence, and younger patients awaiting renal transplantation. CAPD also better preserves residual renal function — the remaining urine-producing capacity of the native kidney — for longer than haemodialysis, which has implications for overall uraemic control and survival in the first 1–2 years on dialysis.

Ideal candidates for CAPD are motivated patients with end-stage renal disease who have sufficient manual dexterity and cognitive capacity to perform the exchanges safely and aseptically, have an intact peritoneum capable of supporting adequate solute clearance and ultrafiltration, and have a home environment conducive to the storage and preparation of dialysis supplies. Age alone is not a contraindication — CAPD is used successfully in elderly patients, children (with caregiver involvement), and patients with diabetes, though the latter require particularly careful monitoring of glycaemic control, as glucose-containing dialysate is absorbed systemically.

Absolute contraindications to CAPD include extensive prior abdominal surgery with peritoneal adhesions that preclude adequate dialysate distribution, active inflammatory bowel disease or diverticulitis, abdominal hernias that cannot be surgically repaired before catheter insertion, severe chronic obstructive pulmonary disease (raised intra-abdominal pressure during dialysate dwell can exacerbate breathlessness), and inability to perform exchanges safely even with assistance. Relative contraindications include morbid obesity (which impairs ultrafiltration), poorly controlled inflammatory conditions affecting the peritoneum, and psychosocial factors — including severe mental health conditions or substance dependence — that compromise technique adherence.

Standard CAPD involves 3–5 manual exchanges per day using 2-litre bags of sterile dialysate, with dwell times of 4–8 hours per exchange. The dialysate is available in glucose concentrations of 1.36%, 2.27%, and 3.86% — higher glucose concentrations create greater osmotic pressure and remove more fluid (ultrafiltration), used when the patient is fluid-overloaded. Icodextrin-based dialysate, a non-glucose polymer, is used for the long overnight dwell in standard CAPD or for the daytime dwell in APD, offering sustained ultrafiltration without the metabolic effects of glucose absorption.

Automated Peritoneal Dialysis (APD) — also called continuous cycling peritoneal dialysis (CCPD) — uses a small cycler machine to perform 3–8 exchanges overnight while the patient sleeps, leaving the abdomen either dry or with a single daytime dwell. APD is preferred by working patients and children, offering greater flexibility and often better compliance. Dual-bag systems with flush-before-fill technique and UV spike protectors have dramatically reduced peritonitis rates — the most common and serious CAPD complication — to below 0.5 episodes per patient-year at high-performing programmes. For patients with inadequate solute clearance on CAPD alone, supplemental haemodialysis sessions or transition to full haemodialysis is necessary. Automated peritoneal dialysis (APD) using a cycler machine delivers exchanges overnight during sleep, providing greater flexibility for working patients. In patients with declining residual kidney function whose metabolic control deteriorates on CAPD alone, supplemental haemodialysis sessions or transition to full haemodialysis is necessary. Monthly biochemical monitoring guides fluid and dietary prescriptions.

CAPD offers several clinically meaningful advantages over in-centre haemodialysis. Cardiovascular stability during dialysis is better preserved — the slow, continuous fluid removal avoids the rapid haemodynamic shifts that cause intradialytic hypotension and are associated with recurrent myocardial stunning and long-term cardiovascular morbidity in haemodialysis patients. Residual renal function declines more slowly with CAPD, particularly in the first 1–2 years of dialysis, resulting in better overall uraemic solute clearance and improved outcomes. Quality of life measures consistently favour CAPD, with patients reporting greater autonomy, freedom from the thrice-weekly haemodialysis schedule, and ability to maintain employment and social activities.

In terms of survival, large registry studies and meta-analyses demonstrate comparable 5-year survival between CAPD and haemodialysis when patients are appropriately selected; some studies show a survival advantage for CAPD in the first 1–2 years, particularly in non-diabetic patients and younger patients. CAPD is associated with greater preservation of haemoglobin levels (reduced need for erythropoiesis-stimulating agents), better blood pressure control with fewer antihypertensive medications, and superior middle-molecule clearance compared to conventional haemodialysis.

Peritonitis — infection of the peritoneal cavity — is the most serious complication of CAPD and the leading cause of technique failure and transition to haemodialysis. It presents with cloudy dialysate effluent, abdominal pain, and fever. The most common causative organisms are Staphylococcus epidermidis and Staphylococcus aureus from touch contamination; Gram-negative peritonitis (from enteric organisms) carries a higher mortality and may result from bowel pathology. Current guidelines recommend a peritonitis rate below 0.5 episodes per patient-year, achievable with modern disconnect systems and rigorous training; untreated peritonitis can progress to catheter loss, adhesion formation, and permanent peritoneal membrane damage.

Catheter-related infections (exit-site and tunnel infections) occur in approximately 0.4–0.6 episodes per patient-year and can seed peritonitis if untreated. Ultrafiltration failure — progressive inability of the peritoneal membrane to remove sufficient fluid — occurs in approximately 20–30% of patients after 5–8 years on CAPD due to peritoneal fibrosis and neovascularisation from chronic glucose exposure; biocompatible low-GDP (glucose degradation product) dialysate solutions slow this progression. Abdominal hernias (umbilical, inguinal, incisional) occur in 10–25% of CAPD patients due to raised intra-abdominal pressure during dialysate dwell and may require surgical repair. Back pain from altered posture with a full peritoneum is common, managed with physiotherapy and ergonomic advice.

Following Tenckhoff catheter insertion (a day-case or overnight surgical procedure under local or general anaesthesia), there is a break-in period of 2–4 weeks during which the patient trains at the renal unit and the catheter exit site heals. During this period, low-volume exchanges in the supine position minimise the risk of leaks. Full-volume exchanges begin after adequate exit-site healing and completion of training. Monthly clinic visits are standard in the first year, with assessment of dialysis adequacy (Kt/V urea, residual renal function), fluid balance, blood pressure, nutritional status, and peritoneal membrane function.

Key monitoring parameters include weekly Kt/V urea (target greater than 1.7) and creatinine clearance, monthly blood tests (electrolytes, bicarbonate, calcium, phosphate, albumin, haemoglobin, HbA1c in diabetics), and annual peritoneal equilibration test to assess membrane transport characteristics. Dietary management is central — CAPD patients require higher protein intake (1.2–1.3 g/kg/day) to compensate for protein losses of 5–12 g per day in the dialysate, careful phosphate restriction, and monitoring of caloric intake given glucose absorption from dialysate (estimated at 100–200 g glucose per day, contributing to weight gain and glycaemic dysregulation in diabetic patients).

CAPD is generally less expensive than in-centre haemodialysis from a healthcare system perspective, as it eliminates the cost of dialysis centre infrastructure, staffing, and machine maintenance — the main costs being dialysate consumables, the initial catheter insertion procedure, and outpatient clinic follow-up. In the United States, the annual cost of CAPD (including dialysate, supplies, nursing support, and clinic visits) is approximately $25,000–$40,000 per year, compared to $80,000–$100,000 for in-centre haemodialysis. Medicare covers dialysis for eligible ESRD patients in the US; private insurance coverage varies.

In India, CAPD dialysate is available through domestic manufacturers at considerably lower cost, and many state health schemes and the Pradhan Mantri National Dialysis Programme subsidise peritoneal dialysis for below-poverty-line patients. The total annual cost of CAPD in India is approximately $3,000–$6,000, representing a fraction of US costs. Patients from high-cost healthcare systems who require long-term dialysis while awaiting transplantation sometimes explore lower-cost CAPD management in destinations such as India, Thailand, or Mexico, though the logistics of dialysate supply, access to specialist nephrology follow-up, and emergency care must be carefully planned.

The principal alternative to CAPD for end-stage renal disease is haemodialysis — either in-centre (typically three sessions of 3–5 hours per week) or home-based (home haemodialysis 5–7 times per week). In-centre haemodialysis is the most widely used renal replacement modality globally due to its availability and the fact that it requires minimal patient involvement. Home haemodialysis offers superior dialysis adequacy and quality of life compared to thrice-weekly in-centre therapy and is comparable to CAPD in terms of patient experience, but requires a partner or caregiver and home modification.

Renal transplantation is the gold-standard treatment for suitable patients with ESRD, offering superior survival and quality of life compared to any form of dialysis, and is the only treatment that actually replaces the function of the native kidney rather than partially substituting for it. CAPD is often used as a bridge to transplantation, preserving residual renal function and maintaining the patient in good condition for transplant. Conservative kidney management — managing ESRD without dialysis, focusing on symptom control and quality of life — is an appropriate alternative for elderly patients with multiple comorbidities for whom dialysis is unlikely to provide meaningful survival benefit.